课题基金 / 基金详情

项目摘要

项目成果

JIAN ZUO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
How the cochleae of humans and other mammals achieve their remarkable sensitivity, frequency selectivity, and enormous dynamic range has been the central question in auditory neurobiology. Two competing mechanisms have been proposed: the mammalian-specific prestin-based outer hair cell (OHC) electromotility and the ubiquitous stereociliary motility. In the previous funding period, we demonstrated that: (1) prestin-based OHC electromotility is necessary for cochlear amplification; (2) prestin plays a novel role in frequency tuning of cochlear passive mechanical responses and their transmission to neural excitation; (3) prestin based OHC electromotility does not appear to adjust the operating point of stereociliary motility; and (4) Glut5, a previously hypothesized OHC motor protein, is undetectable in OHCs and does not contribute to cochlear amplification. Based on these and other advances, we propose a unified amplificatory mechanism that stipulates stereociliary motility for tuning and electromotility for power. However, it remains controversial whether prestin plays both active and passive mechanical roles and whether prestin-based electromotility performs the necessary cycle-by-cycle feedback. Furthermore, it is still unclear how prestin drives coordinated changes in the lateral plasma membrane and underlying cytoskeletal structure for OHC electromotility. To further elucidate prestin's roles in OHC electromotility and cochlear amplification, we will pursue the following Specific Aims: 1) Determine how prestin-based OHC electromotility generates cochlear amplification. 2). Determine the distribution, trafficking, and membrane mobility of prestin in OHCs. Recently, two putative mutations in the human prestin gene have been reported to cause deafness. Hearing loss induced by large doses of sodium salicylate (aspirin) has been attributed to a reduction in prestin-based OHC electromotility. Moreover, prestin is likely the common effector of hearing loss in some patients with high-frequency hearing loss. Our studies will contribute greatly to our understanding of cochlear amplification and the pathophysiology of deafness caused by a variety of genetic and environmental factors.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41598-017-04279-3
发表时间: 2017-07-12
期刊: Scientific reports
影响因子: 4.6
作者: [Lukashkina VA, Yamashita T, Zuo J, Lukashkin AN, Russell IJ]
通讯作者: Russell IJ
Aldh inhibitor restores auditory function in a mouse model of human deafness.
Aldh 抑制剂可恢复人类耳聋小鼠模型的听觉功能。
DOI: 10.1371/journal.pgen.1009040
发表时间: 2020-09
期刊: PLoS genetics
影响因子: 4.5
作者: [Zhu GJ, Gong S, Ma DB, Tao T, He WQ, Zhang L, Wang F, Qian XY, Zhou H, Fan C, Wang P, Chen X, Zhao W, Sun J, Chen H, Wang Y, Gao X, Zuo J, Zhu MS, Gao X, Wan G]
通讯作者: Wan G
DOI: 10.1371/journal.pone.0113990
发表时间: 2014
期刊: PloS one
影响因子: 3.7
作者: [Cai Q, Wang B, Coling D, Zuo J, Fang J, Yang S, Vera K, Hu BH]
通讯作者: Hu BH
DOI: 10.1371/journal.pgen.1007552
发表时间: 2018-07
期刊: PLoS genetics
影响因子: 4.5
作者: [Yamashita T, Zheng F, Finkelstein D, Kellard Z, Carter R, Rosencrance CD, Sugino K, Easton J, Gawad C, Zuo J]
通讯作者: Zuo J
13
    Drug Discovery and Delivery Core
    • 批准号:
      10364614
    • 项目类别:
    • 资助金额:
      $16.22万
    • 财政年份:
      2021
    • 负责人:
      JIAN ZUO
    • 依托单位:
    Drug Discovery and Delivery Core
    • 批准号:
      10579962
    • 项目类别:
    • 资助金额:
      $14.33万
    • 财政年份:
      2021
    • 负责人:
      JIAN ZUO
    • 依托单位:
    Drug Discovery and Delivery Core
    • 批准号:
      10090989
    • 项目类别:
    • 资助金额:
      $25.92万
    • 财政年份:
      2021
    • 负责人:
      JIAN ZUO
    • 依托单位:
    Discovery of In Vivo Small Molecules for Hearing Protection Against Cisplatin and Noise
    • 批准号:
      9672287
    • 项目类别:
    • 资助金额:
      $48.3万
    • 财政年份:
      2016
    • 负责人:
      JIAN ZUO
    • 依托单位:
    海外基金